<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" dms-id="H90FAD15FB1F144CC844BB2E803EDC21A" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 639 RH: Improving Regulatory Transparency for New Medical Therapies Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-03-16</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IB</distribution-code> 
<calendar display="yes">Union Calendar No. 26</calendar>
<congress display="yes">114th CONGRESS</congress> <session display="yes">1st Session</session> 
<legis-num>H. R. 639</legis-num>
<associated-doc role="report" display="yes">[Report No. 114–41, Part I]</associated-doc> 
<current-chamber display="yes">IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150202">February 2, 2015</action-date> 
<action-desc><sponsor name-id="P000373">Mr. Pitts</sponsor> (for himself, <cosponsor name-id="P000034">Mr. Pallone</cosponsor>, and <cosponsor name-id="G000410">Mr. Gene Green of Texas</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00" added-display-style="italic" deleted-display-style="strikethrough">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on the <committee-name committee-id="HJU00">Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc> 
</action> 
<action>
<action-date>March 16, 2015</action-date>
<action-desc>Additional sponsor: <cosponsor name-id="M001159">Mrs. McMorris Rodgers</cosponsor></action-desc>
</action>
<action>
<action-date date="20150316">March 16, 2015</action-date>
<action-desc>Reported from the Committee on <committee-name committee-id="HIF00" added-display-style="italic" deleted-display-style="strikethrough">Energy and Commerce</committee-name> with amendments</action-desc>
<action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction> 
</action>
<action>
<action-date date="20150316">March 16, 2015</action-date>
<action-desc>The<committee-name committee-id="HJU00"> Committee on the Judiciary</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc>
<action-instruction>For text of introduced bill, see copy of bill as introduced on February 2, 2015</action-instruction>
</action>
<action display="yes">
<action-desc display="yes"><pagebreak/></action-desc>
</action>
<legis-type>A BILL</legis-type> 
<official-title display="yes">To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.<pagebreak/></official-title> 
</form> 
<legis-body display-enacting-clause="yes-display-enacting-clause" changed="added" style="OLC" committee-id="HIF00" reported-display-style="italic" id="H78B70180002E47E793ED330E57F85654">
<section id="H86583B8EAEF6449F9775FA9AE6B55C2B" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Improving Regulatory Transparency for New Medical Therapies Act</short-title></quote>.</text></section> <section id="H8DBA0E15F2EC40EC9C5E7C28AD421A1A"><enum>2.</enum><header>Scheduling of substances included in new FDA-approved drugs</header> <subsection id="H609D6B200301450BB4EDFCC016AE9D6C"><enum>(a)</enum><header>Effective date of approval</header> <paragraph id="H2B48524522B8477CBB3D0671EEF0E8EF"><enum>(1)</enum><header>Effective date of drug approval</header><text>Section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) is amended by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="H8F7342B3BF8649F4A48EB99E70512657" style="OLC">
<subsection id="H0108394B29AE45CAB9A8901EDB575F7B"><enum>(x)</enum><header>Date of approval in the case of recommended controls under the CSA</header>
<paragraph id="H335F92DC255F4611990290A50338E751"><enum>(1)</enum><header>In general</header><text>In the case of an application under subsection (b) with respect to a drug for which the Secretary provides notice to the sponsor that the Secretary intends to recommend controls under the Controlled Substances Act, approval of such application shall not take effect until the interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act.</text></paragraph> <paragraph id="HD14A694D4AB14953A5C450E7ACABF7D4"><enum>(2)</enum><header>Date of approval</header><text>For purposes of this section, with respect to an application described in paragraph (1), the term <term>date of approval</term> shall mean the later of—</text>
<subparagraph id="H5A4EFA94122F4F93A69EA20198F70549"><enum>(A)</enum><text>the date an application under subsection (b) is approved under subsection (c); or</text></subparagraph> <subparagraph id="H8FF8983808EF49F992C10EAE73D9B665"><enum>(B)</enum><text>the date of issuance of the interim final rule controlling the drug.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph>
<paragraph id="HAB34FDBAE2964A58808755F1CD670D02"><enum>(2)</enum><header>Effective date of approval of biological products</header><text>Section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) is amended by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="HA10E49C41CFD45ABAFBAAD41617BC9E0" style="OLC"> <subsection id="H124D5A3F0AA44455B724BB351097CEEB"><enum>(n)</enum><header>Date of approval in the case of recommended controls under the CSA</header> <paragraph id="HDF916245EFB341A68E5187B85FC64F36"><enum>(1)</enum><header>In general</header><text>In the case of an application under subsection (a) with respect to a biological product for which the Secretary provides notice to the sponsor that the Secretary intends to recommend controls under the Controlled Substances Act, approval of such application shall not take effect until the interim final rule controlling the biological product is issued in accordance with section 201(j) of the Controlled Substances Act.</text></paragraph>
<paragraph id="H97C31DA517564370BA8B45498E87EB54"><enum>(2)</enum><header>Date of approval</header><text display-inline="yes-display-inline">For purposes of this section, with respect to an application described in paragraph (1), references to the date of approval of such application, or licensure of the product subject to such application, shall mean the later of—</text> <subparagraph id="H406C23456A014FEA9567F67ED2FFFBA9"><enum>(A)</enum><text>the date an application is approved under subsection (a); or</text></subparagraph>
<subparagraph id="HE35B72282FB5478C958754C1169E91D8"><enum>(B)</enum><text>the date of issuance of the interim final rule controlling the biological product.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph> <paragraph id="HEA05D22E4EAF4DC8932F31BCAF6C2612"><enum>(3)</enum><header>Effective date of approval of animal drugs</header> <subparagraph id="H10A9A5A2C2CD4C46807F22E40849F301"><enum>(A)</enum><header>In general</header><text>Section 512 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360b">21 U.S.C. 360b</external-xref>) is amended by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="HD64147D310F64F7DA2BAA28BCA5E9987" style="OLC">
<subsection id="H587F3B386D83479A9053DD339715DEE3"><enum>(q)</enum><header>Date of approval in the case of recommended controls under the CSA</header>
<paragraph id="HA9391D373FB743A8A553354A9BAD75E0"><enum>(1)</enum><header>In general</header><text>In the case of an application under subsection (b) with respect to a drug for which the Secretary provides notice to the sponsor that the Secretary intends to recommend controls under the Controlled Substances Act, approval of such application shall not take effect until the interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act.</text></paragraph> <paragraph id="H8E73E828E2BA4A2BBFF60D19A9BD0B0C"><enum>(2)</enum><header>Date of approval</header><text>For purposes of this section, with respect to an application described in paragraph (1), the term <term>date of approval</term> shall mean the later of—</text>
<subparagraph id="HFD4F91C221F0464C9442621907F29926"><enum>(A)</enum><text>the date an application under subsection (b) is approved under subsection (c); or</text></subparagraph> <subparagraph id="HF66084B05C7E48A28E7D5DE51B224C0B"><enum>(B)</enum><text>the date of issuance of the interim final rule controlling the drug.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph>
<subparagraph id="HBFFA585D2D8A4C2BA74A3E1AEEB42CEA"><enum>(B)</enum><header>Conditional approval</header><text>Section 571(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ccc">21 U.S.C. 360ccc(d)</external-xref>) is amended by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="HAC2035F3C5204B25BF9935C8AC1ECFB2" style="OLC"> <paragraph id="H583ACAA0CE8D4BFAB5B4192D5CFEEF15"><enum>(4)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="HC8559BF1247145E8A6DDB75F5539DCD0"><enum>(A)</enum><text>In the case of an application under subsection (a) with respect to a drug for which the Secretary provides notice to the sponsor that the Secretary intends to recommend controls under the Controlled Substances Act, conditional approval of such application shall not take effect until the interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act.</text></subparagraph>
<subparagraph id="H212129B8C2314CB688FEE72FFF459307" indent="up1"><enum>(B)</enum><text>For purposes of this section, with respect to an application described in subparagraph (A), the term <term>date of approval</term> shall mean the later of—</text> <clause id="H02AA2DE3175F428DBEE451AD8B796AE1"><enum>(i)</enum><text>the date an application under subsection (a) is conditionally approved under subsection (b); or</text></clause>
<clause id="HA0172079D35B48B29E4FE1DBC5FB6D24"><enum>(ii)</enum><text>the date of issuance of the interim final rule controlling the drug.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph> <subparagraph id="H7DEAC4C3902F492993848FDA01B5A79E"><enum>(C)</enum><header>Indexing of legally marketed unapproved new animal drugs</header><text>Section 572 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ccc-1">21 U.S.C. 360ccc–1</external-xref>) is amended by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="H2F6D21A5B20C49FFA95B9DBEA72E3FC8" style="OLC">
<subsection id="H09604FCAEE7D48EA85EE3AD0B1D5150C"><enum>(k)</enum><text>In the case of a request under subsection (d) to add a drug to the index under subsection (a) with respect to a drug for which the Secretary provides notice to the person filing the request that the Secretary intends to recommend controls under the Controlled Substances Act, a determination to grant the request to add such drug to the index shall not take effect, and the Secretary shall not list the drug on such index, until the interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph> <paragraph id="HA9609E39394F48739F286D6AFDF6D20E"><enum>(4)</enum><header>Date of approval for designated new animal drugs</header><text>Section 573(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ccc-2">21 U.S.C. 360ccc–2(c)</external-xref>) is amended by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="H7CC0729C0A42446FA148048B3BD3412C" style="OLC">
<paragraph id="H0A71EFFE22BF412DB3A7245FAB51BA69"><enum>(3)</enum><text>For purposes of determining the 7-year period of exclusivity under paragraph (1) for a drug for which the Secretary intends to recommend controls under the Controlled Substances Act, the drug shall not be considered approved or conditionally approved until the date that the interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> <subsection id="H2E248D68EA944544B7CA288FE45751E6"><enum>(b)</enum><header>Scheduling of newly approved drugs</header><text display-inline="yes-display-inline">Section 201 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811</external-xref>) is amended by inserting after subsection (i) the following:</text>
<quoted-block id="H6DB5512FD1E147A88942E969487A31D5" style="OLC">
<subsection id="H5345491C13164A99865DDE43CC1ED372"><enum>(j)</enum>
<paragraph commented="no" display-inline="yes-display-inline" id="HA510C41D5C4F457F891AE89E6E99311F"><enum>(1)</enum><text display-inline="yes-display-inline">With respect to a drug referred to in subsection (f), if the Secretary of Health and Human Services recommends that the Attorney General add the drug to schedule II, III, IV, or V pursuant to subsections (a) and (b), the Attorney General shall, not later than 90 days after the date described in paragraph (2), issue an interim final rule controlling the drug in accordance with such subsections and section 202(b) using the procedures described in paragraph (3).</text></paragraph> <paragraph id="H021AFF8A17024CACB7222D4CD1BBAAC1" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline">The date described in this paragraph shall be the later of—</text>
<subparagraph id="H6FE58EC17C434C60BD27A03FAC68D79D"><enum>(A)</enum><text display-inline="yes-display-inline">the date on which the Attorney General receives the scientific and medical evaluation and recommendations from the Secretary of Health and Human Services in accordance with subsection (b); or</text></subparagraph> <subparagraph id="HB346E59F7923405493EDA8BE17A7A40C"><enum>(B)</enum><text display-inline="yes-display-inline">the date on which the Attorney General receives notification from the Secretary of Health and Human Services that the Secretary has approved an application under section 505(c), 512, 571, or 572 of the Federal Food, Drug, and Cosmetic Act or section 351(a) of the Public Health Service Act with respect to the drug described in paragraph (1).</text></subparagraph></paragraph>
<paragraph id="HB42E0D77C1434F82918727E5CE45B4FD" indent="up1"><enum>(3)</enum><text display-inline="yes-display-inline">A rule issued by the Attorney General under paragraph (1) shall be in accordance with the procedures provided in subsection (a), except that the rule shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor. After publication of the interim final rule, the Attorney General shall issue a final rule in accordance with the procedures provided in subsection (a).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H88E34A6DA17142EAB2D8F2B8C655DAD6"><enum>(c)</enum><header>Extension of patent term</header><text>Section 156 of title 35, United States Code, is amended—</text>
<paragraph id="H6CE1F825AF724C2D9DC95AD191190A05"><enum>(1)</enum><text>in subsection (d)(1), in the matter preceding subparagraph (A), by inserting <quote>, or in the case of a drug product described in subsection (i) within the sixty-day period beginning on the covered date (as defined in subsection (i))</quote> after <quote>marketing or use</quote>; and</text></paragraph> <paragraph id="HE668D89EE3984D389FD328D4293E186A"><enum>(2)</enum><text>by adding at the end the following:</text>
<quoted-block display-inline="no-display-inline" id="HAA1A0292787642E586E6CC59FA1704E7" style="OLC">
<subsection id="HC5C1B6EE4DAC44C4B7A735E62F98D477"><enum>(i)</enum>
<paragraph commented="no" display-inline="yes-display-inline" id="H02E8F5F9C3BC435A85DCDFEE89FF6EFC"><enum>(1)</enum><text>For purposes of this section, if the Secretary of Health and Human Services provides notice to the sponsor of an application or request for approval, conditional approval, or indexing of a drug product for which the Secretary intends to recommend controls under the Controlled Substances Act, beginning on the covered date, the drug product shall be considered to—</text> <subparagraph id="HCE83D3201E73481DB15A91A77E33164E" indent="up1"><enum>(A)</enum><text>have been approved; and</text></subparagraph>
<subparagraph id="H3CA312EA31A8425BBFA71FC78CBE0742" indent="up1"><enum>(B)</enum><text>have permission for commercial marketing or use.</text></subparagraph></paragraph> <paragraph id="HA76A2299136F4A9F93C78309AC525416" indent="up1"><enum>(2)</enum><text>In this subsection, the term <term>covered date</term> means the later of—</text>
<subparagraph id="H298510126B49473EAADF37C5CC63C76E"><enum>(A)</enum><text>the date an application is approved—</text> <clause id="H1663AF06A7974A799C12AD13EA2440DC"><enum>(i)</enum><text>under section 351(a)(2)(C) of the Public Health Service Act; or</text></clause>
<clause id="H400D847720C74933ADE2F8E9275B8677"><enum>(ii)</enum><text>under section 505(b) or 512(c) of the Federal Food, Drug, and Cosmetic Act; </text></clause></subparagraph> <subparagraph id="HB7E7F7DA6792446B84F1113F3E757DBF"><enum>(B)</enum><text>the date an application is conditionally approved under section 571(b) of the Federal Food, Drug, and Cosmetic Act;</text></subparagraph>
<subparagraph id="H70D46C47EBC443BDA454054162AE4D4F"><enum>(C)</enum><text>the date a request for indexing is granted under section 572(d) of the Federal Food, Drug, and Cosmetic Act; or</text></subparagraph> <subparagraph id="HD211C335E0454416950C39B82F186AF0"><enum>(D)</enum><text>the date of issuance of the interim final rule controlling the drug under section 201(j) of the Controlled Substances Act.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section>
<section id="H17CE4DE0016947F68B6F4197F7A4DD12"><enum>3.</enum><header>Enhancing new drug development</header><text display-inline="no-display-inline">Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="HCC33D8629818428ABA588CD25D717AFB" style="OLC"> <subsection id="H2DF8B0DC27D54DA48C9F6784C39C1304"><enum>(i)</enum> <paragraph commented="no" display-inline="yes-display-inline" id="H883D9232205747259A93D88D521CA442"><enum>(1)</enum><text display-inline="yes-display-inline">For purposes of registration to manufacture a controlled substance under subsection (d) for use only in a clinical trial, the Attorney General shall register the applicant, or serve an order to show cause upon the applicant in accordance with section 304(c), not later than 180 days after the date on which the application is accepted for filing.</text></paragraph>
<paragraph commented="no" display-inline="no-display-inline" id="H59CDB8B692D24128AEEBD986ADEB357A" indent="up1"><enum>(2)</enum><text>For purposes of registration to manufacture a controlled substance under subsection (a) for use only in a clinical trial, the Attorney General shall, in accordance with the regulations issued by the Attorney General, issue a notice of application not later than 90 days after the application is accepted for filing. Not later than 90 days after the date on which the period for comment pursuant to such notice ends, the Attorney General shall register the applicant, or serve an order to show cause upon the applicant in accordance with section 304(c), unless the Attorney General has granted a hearing on the application under section 1008(i) of the Controlled Substances Import and Export Act.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section> </legis-body><official-title-amendment>Amend the title so as to read: <quote>A bill to amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing, and for other purposes.</quote>.</official-title-amendment> <endorsement display="yes"> <action-date date="20150316">March 16, 2015</action-date> <action-desc>Reported from the Committee on <committee-name committee-id="HIF00" added-display-style="italic" deleted-display-style="strikethrough">Energy and Commerce</committee-name> with amendments</action-desc> <action-date date="20150316">March 16, 2015</action-date> <action-desc>The<committee-name committee-id="HJU00"> Committee on the Judiciary</committee-name> discharged; committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc></endorsement> </bill> 

